Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A small phase 2 trial found that pharmaceutically manufactured, THC-free CBD (CardiolRx) significantly reduced chest pain and normalized inflammatory markers in patients with recurrent pericarditis. Mean pain scores dropped from 5.8 to 2.1 after just 8 weeks, and 71% of patients who continued into the extension phase remained recurrence-free. Researchers say it could be a valuable option before escalating to corticosteroids or injectable IL-1 blockers.
Could CBD be the next tool in the fight against recurrent pericarditis?
A phase 2, open-label trial published in the Journal of the American Heart Association suggests that pharmaceutically manufactured, THC-free CBD (CardiolRx, Cardiol Therapeutics) may offer meaningful relief for patients with recurrent pericarditis. Taken orally twice daily, the formulation works by inhibiting the NLRP3 inflammasome — a key driver of pericardial inflammation — and was well tolerated across the 27-patient study cohort.
After 8 weeks of treatment, average pain scores fell sharply, and the majority of patients with elevated inflammatory markers saw those levels normalize. Nearly 89% of participants opted into an 18-week extension period, during which most remained recurrence-free and some were successfully weaned off corticosteroids.
By the Numbers:
Why it matters: Recurrent pericarditis is notoriously difficult to manage, and current escalation therapies — corticosteroids and injectable IL-1 blockers — carry high recurrence risks upon discontinuation. An oral, well-tolerated CBD option could fill a critical gap as a second-line therapy, potentially sparing patients from more aggressive treatments.
